Search

Flecainide

[A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

DDP-200

DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

Laronidase

Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line.

Mitiglinide

It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels.

Amitifadine

Heptabarbital

Heptabarbital is an intermediate or short term barbiturate used mainly for sedation and hypnosis.

Influenza A virus A/Victoria/361/2011 (H3N2) recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza B virus B/Wisconsin/1/2010 recombinant hemagglutinin antigen

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

Influenza A virus A/Christchurch/16/2010 NIB-74 (H1N1) antigen (propiolactone inactivated)

Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen